Figure 6: Properties of mutant B/Brisbane/60/2008 viruses and HAs.
From: A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action
(a) Plaque reduction assay. 100 plaque-forming units (pfu) of each virus was incubated with varying concentrations of 46B8 for 1 h prior to infection of MDCK cells. At 1 h post infection, the inoculum was removed and cells were overlaid with varying concentrations of 46B8 in agarose. At day 4 post infection, the numbers of plaques were counted for each virus and normalized to the number at the lowest antibody concentration. The assay was done in triplicate. (b) 293 T cells expressing the WT or mutant B/Brisbane/60/2008 HAs were incubated with 34B5 (left panel) or 46B8 (middle and right panels) at pH 7.0 (left and middle panels) or 4.8 (right panel). Flow cytometry profiles are shown. Mock, mock transfected cells. (a: mean and s.e.m.)
